secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTELO BIOSCIENCES, INC. (ARTL)
CIK:        0001621221
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001640334-22-001683
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artelo Biosciences reports Q2 2022 net loss of $2.4M, announces 1-for-15 reverse stock split to regain Nasdaq compliance
--------------------------------------------------------------------------------

- Net loss $2.4M ($0.87/share) in Q2 2022 vs $2.3M ($1.45/share) in Q2 2021; operating expenses $2.4M.
- Cash and investments $21.3M at June 30, 2022, down from $25.6M at Dec 31, 2021; expected to fund operations through end of 2023.
- 15-for-1 reverse stock split effective August 10, 2022 to improve marketability and regain Nasdaq compliance; shares reduced from 42.6M to ~2.8M.
- CAReS study of ART27.13 progresses to fourth cohort (650 mcg); Phase 2b enrollment expected Q4 2022.
- Preclinical data for ART26.12 shows efficacy in chemotherapy-induced neuropathy models.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621221/000164033422001683/0001640334-22-001683-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621221/000164033422001683/artl_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-22-001683

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer